公司公告，董事会同意使用不超过250,000,000.00元的暂时闲置募集资金临时补充流动资金，使用期限 不超过董事会审议通过之日起12个月，资金可滚动使用，到期归还至募集资金专户。此次调整系因原募 投项目"跨境电商智慧物流中心"已结项，剩余募集资金23,988.82万元变更用于"自贸港云智国际分拨中 心"项目。公司已归还前次补充流动资金的闲置募集资金。本次使用不影响募投项目建设，不改变募集 资金用途。 公司公告，董事会审议通过使用不超过28,000万元的暂时闲置募集资金进行现金管理，投资期限不超过 12个月，资金本金及收益可滚动使用，有效期为董事会审议通过之日起12个月。投资产品为银行或其他 金融机构发行的安全性高、流动性好的低风险保本型理财产品。董事会授权管理层在额度内进行投资决 策并签署相关文件，财务部门组织实施，内部审计部门监督。监事会及保荐机构均发表同意意见。 国泰海通证券作为保荐机构，对公司使用不超过250,000,000.00元闲置募集资金临时补充流动资金事项 出具核查意见，认为该行为符合相关法规规定，无异议。截至2025年6月30日，募集资金累计投入 512,671,720.00元，其中"跨境 ...

Core Viewpoint - The company, Shaanxi Meibang Pharmaceutical Group Co., Ltd., has announced the use of temporarily idle raised funds for cash management, specifically through a financial product with a total investment of 15 million yuan [1][4]. Group 1: Financial Management - The entrusted financial management is conducted by CITIC Bank, with a total amount of 15 million yuan allocated to the "Anying Xiang Fixed Income Stable Profit One Month Holding Period 32 C" product [1][7]. - The company aims to enhance the efficiency of fund utilization while ensuring that the investment projects funded by the raised capital are not affected [4][11]. - The maximum amount approved for cash management is 20 million yuan from idle raised funds and 60 million yuan from idle self-owned funds, with the ability to roll over the amount within the validity period of the resolution [1][8]. Group 2: Previous Financial Management - The previous financial management involved the redemption of funds from a product named "Tongying Xiang Fixed Income Stable Seven-Day Holding Product 1," with actual returns aligning with expectations [2][3]. - The company has utilized a total of 9 million yuan in financial products over the last twelve months, with a maximum single-day investment of 3 million yuan, representing 2.67% of the net assets for the past year [13]. Group 3: Investment Product Details - The current financial product has a duration of 30 days, with an expected annualized return rate of 3.86% [7]. - The company ensures that the investment products are of high safety and liquidity, complying with the requirements for cash management without altering the intended use of raised funds [6][11]. Group 4: Approval Process - The decision to use idle funds for cash management was approved during the third board meeting and the fifth supervisory board meeting held on April 24, 2025, and subsequently ratified at the annual shareholders' meeting on May 16, 2025 [1][8]. - The supervisory board and the sponsor institution have both expressed agreement with the company's cash management strategy, confirming compliance with relevant regulations [11].